From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma

Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...
WIB_icon

Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management

Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...
WIB_icon

Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia

Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
WIB_icon

Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia

Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...

Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma

While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...

Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...

In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
WIB_icon

Insurance Status Contributes to Survival Disparities in Follicular Lymphoma

Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...
WIB_icon

No Benefit, but Excess Toxicity, With Rivaroxaban for Patients With High-Risk Antiphospholipid Syndrome

Rivaroxaban and other direct oral anticoagulants are used as an alternative to warfarin for the prevention of thromboembolism, but data do not support routine...
WIB_icon

Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.